Discontinued — last reported Q4 '23
Business Segments · D&A
Covance Drug Development — D&A
Labcorp Holdings Covance Drug Development — D&A remained flat by 0.0% to $28.13M in Q4 2023 compared to the prior quarter. Year-over-year, this metric declined by 0.3%, from $28.20M to $28.13M. Over 2 years (FY 2021 to FY 2023), Covance Drug Development — D&A shows relatively stable performance with a 2.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2014
Last reportedQ4 2023Feb 26, 2024
Rolls up toD&A
How to read this metric
Changes in this metric often correlate with the level of capital investment and the history of M&A activity.
Detailed definition
The total non-cash expense representing the wear and tear of physical property and the expiration of intangible assets w...
Peer comparison
Used to calculate EBITDA and assess the capital intensity of the business segment.
Metric ID:
lh_segment_covance_drug_development_depreciation_and_amortizationHistorical Data
3 years
| FY'21 | FY'22 | FY'23 | |
|---|---|---|---|
| Value | $106.30M | $112.80M | $112.50M |
| YoY Change | — | +6.1% | -0.3% |
Range$106.30M – $112.80M
CAGR+2.9%
Avg YoY Growth+2.9%
Median YoY Growth+2.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — d&a?
- Labcorp Holdings (LH) reported covance drug development — d&a of $28.13M in Q4 2023.
- How has Labcorp Holdings's covance drug development — d&a changed year-over-year?
- Labcorp Holdings's covance drug development — d&a decreased by 0.3% year-over-year, from $28.20M to $28.13M.
- What is the long-term trend for Labcorp Holdings's covance drug development — d&a?
- Over 2 years (2021 to 2023), Labcorp Holdings's covance drug development — d&a has grown at a 2.9% compound annual growth rate (CAGR), from $106.30M to $112.50M.
- What does covance drug development — d&a mean?
- The total annual cost of physical asset wear and intangible asset expiration.